
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
METTL3 CRISPR Activation Plasmid (bovine) | sc-437359-ACT | 20 µg | $397.00 | |||
METTL3 CRISPR Activation Plasmid (bovine2) | sc-437359-ACT-2 | 20 µg | $397.00 |
METTL3 encodes the catalytic core of the N6-methyladenosine (m6A) RNA methyltransferase complex, a major epitranscriptomic regulator of mRNA and non-coding RNA fate in bovine cells. By depositing m6A marks, METTL3 influences RNA splicing, nuclear export, translation efficiency, and transcript stability, integrating with pathways that govern cell cycle progression, differentiation programs, stress responses, and innate immune signaling. Altered METTL3 activity is broadly linked to dysregulated gene expression networks and phenotypes relevant to oncogenic transformation, inflammatory signaling, and developmental defects across species. In bovine biomedical and comparative models, METTL3 modulation supports mechanistic studies of RNA methylation-dependent control of cellular state and gene regulatory circuitry.
METTL3 CRISPR Activation Plasmid (bovine) provides a targeted, non-destructive approach to upregulating endogenous expression without altering the underlying DNA sequence.
METTL3 CRISPR Activation Plasmid (bovine) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous METTL3 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native locus and enabling the study of METTL3-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of METTL3 pathway restoration in tumor cells with silenced or reduced expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.